Nivolumab

BNF:
8.1.5
Status:
Do Not Prescribe (DNP), Red
Decision Date:
None
 

Comments

RED1,8: For the treatments of advanced squamous non-small cell lung cancer in adults who have previously received chemotherapy (Decision date - August 2015)

RED1,2,3,8: NICE TA384 for treating advanced (unresectable or metastatic) melanoma (Decision date - March 2016)

RED1,2,3,8: NICE TA400 nivolumab in combination with ipilimumab for treating advanced melanoma. (Decision date- August 2016)

RED1,2,3,8: NICE TA417 nivolumab for previously treated advanced renal cell carcinoma. (Decision date- December 2016)

RED1,2,3,8: NICE TA462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (Decision date - August 2017)

RED1,2,3,8: NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer. (Decision date - December 2017)

RED1,2,3,8: NICE TA484: Nivolumab for previously treated nonsquamous non-small-cell lung cancer. (Decision date - December 2017)

RED1,2,3,8: NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy. (Decision date - December 2017)

RED1,2,3,8: NICE TA558 : adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease. (Decision date - Feb 2019)

RED1,2,3,8: NICE TA581 - with ipilimumab for untreated advanced renal cell carcinoma. (Decision date - June 2019)

RED1,2,3,8: NICE TA655 for treating locally advanced or metastatic squamous NSCLC. NHSE commissioned.

RED1,2,3,8: NICE TA684 - adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease. Replaces NICE TA558. (Decision date - April 2021)

RED1,2,3,8: NICE TA707 - Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer (Decision date - July 2021)

RED1,2,3,8NICE TA713 - for non-squamous non-small-cell lung cancer (NSCLC) in adults after chemotherapy (Decision date - August 2021)

RED1,2,3,8NICE TA716 - Nivolumab plus ipilimumab for treating metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (Decision date - August 2021)

RED1,2,3,8: NICE TA724 - Nivolumab with ipilimumab and chemotherapy for untreated metastatic nonsmall-cell lung cancer (Decision date - Oct 2021)

DO NOT PRESCRIBE (DNP)6: NICE TA530: For treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (Decision date - August 2018)

Do Not Prescribe (DNP) Drug Classifications

  • 6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
  • 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again

Derby and Derbyshire CCG

Derby and Derbyshire CCG

Please click the button to navigate to our app

Redirect to app